S-1: Pasithea Therapeutics Eyes $15.4 Million in New Public Offering to Fund CNS Disorder Treatments

Pasithea Therapeutics launches a public offering of common stock and warrants, aiming to raise approximately $15.4 million to advance its pipeline of treatments for central nervous system disorders and other diseases.

Summary

• Pasithea Therapeutics Corp. is undertaking a public offering to sell up to 3,246,753 shares of common stock, along with warrants to purchase up to 6,493,506 additional shares.
• The offering also includes pre-funded warrants for certain purchasers who would exceed ownership limits, exercisable at $0.001 per share.
• Each share of common stock or pre-funded warrant is paired with a Series C Common Warrant and a Series D Common Warrant, both exercisable at $1.54 per share, with varying expiration dates.
• The offering is expected to conclude by May 31, 2025, and H.C. Wainwright & Co. is acting as the exclusive placement agent.
• The company intends to use the net proceeds, estimated at $4.3 million, for general corporate purposes, including research, clinical trials, and potential acquisitions.
• Pasithea is an emerging growth company and a smaller reporting company, allowing it to take advantage of reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The company is actively developing promising treatments and has achieved some regulatory milestones. However, it faces financial challenges, including ongoing losses and the need for additional capital. The sentiment is neutral, reflecting the balance of these factors.

Positives

• The company is advancing PAS-004, a MEK inhibitor, into a Phase 1/1b clinical trial in adult NF1-PN patients followed by pediatric NF1-PN patients.
• PAS-004 has received orphan-drug designation from the FDA for the treatment of NF1.
• The company has completed dosing through cohort 5 in its FIH Phase 1 Dose Escalation Study and are currently dosing three patients in cohort 6 (30 mg capsule).
• No DLTs, rash or ocular toxicities have been observed in any of the cohorts assessed to date, and all treatment related adverse events have been either Grade 1 or Grade 2, which support PAS-004s potential favorable safety and tolerability profile.
• PAS-004 has demonstrated favorable PK properties, including a long half-life of approximately 60 hours, a low peak to trough (Cmax to Cmin) ratio as compared to other FDA approved MEK inhibitors, and linear pharmacokinetics.

Negatives

• The company has incurred losses since inception and anticipates that it will continue to incur losses for the foreseeable future.
• The company is uncertain when or if it will be able to achieve or sustain profitability.
• The company will require additional capital to fund its operations, and if it fails to obtain necessary financing, it may not be able to complete the development and commercialization of its drugs.
• The report of the company's independent registered public accounting firms for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• There is no public market for the Common Warrants or Pre-Funded Warrants being offered by the company in this offering.
• The Common Warrants are not exercisable until the Warrant Stockholder Approval; provided, however, that if the Pricing Conditions are met, the Common Warrants will be exercisable upon issuance.

Risks

• The company has a limited operating history and expects to incur significant operating losses.
• The development and commercialization of product candidates is a lengthy and expensive process with an uncertain outcome.
• The company is dependent on third parties for various aspects of its operations.
• The company faces risks related to intellectual property protection and potential infringement claims.
• Global economic and market conditions could negatively impact the company's business and access to capital markets.
• The company's failure to maintain compliance with Nasdaqs continued listing requirements could result in the desilting of its securities.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• You will experience immediate and substantial dilution in the net tangible book value of the shares of common stock you purchase in this offering and may experience additional dilution in the future.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, including ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.

Industry Context

The company is operating in the competitive biotechnology industry, focusing on treatments for CNS disorders and RASopathies, areas with significant unmet medical needs and potential for innovation.

Comparison to Industry Standards

• The company's approach to developing treatments for CNS disorders aligns with industry trends focusing on novel targets and personalized medicine.
• The company's lead product candidate, PAS-004, a MEK inhibitor, is targeting RASopathies, including neurofibromatosis type 1 (NF1), a number of MAPK pathway driven tumors, such as BRAFv600 and BRAF fusion tumors, among other indications including ETS2 driven diseases, such as inflammatory bowel disease, primary sclerosing cholangitis and ankylosing spondylitis.
• The company's clinical development plan for PAS-004 is to advance PAS-004 into a Phase 1/1b clinical trial in adult NF1-PN patients followed by pediatric NF1-PN patients and ultimately complete registrational clinical trials in these patient populations, as they represent the initial indications for which we plan to seek marketing approval for PAS-004.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's continued growth and development of new treatments.
• Patients with CNS disorders and RASopathies could potentially benefit from the company's pipeline of therapeutic candidates.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Complete the public offering.
• Advance PAS-004 into Phase 1/1b clinical trials.
• Continue development of PAS-003 and PAS-001.
• Seek potential acquisitions or licensing opportunities.

Key Dates

Keywords

public offering, warrants, common stock, Pasithea Therapeutics, CNS disorders, MEK inhibitor, PAS-004, clinical trials, biotechnology, financing